Evolus, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
EOLS Nasdaq 2834 www.evolus.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Evolus, Inc.

Evolus to Participate in The Jefferies Global Healthcare Conference - May 19th, 2026 6:30 am
3 High-Growth Insider-Owned Companies With Earnings Surging Up To 80% - May 15th, 2026 5:35 am
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe - May 11th, 2026 6:30 am
Evolus, Inc. Q1 2026 Earnings Call Summary - May 4th, 2026 6:23 pm
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates - May 4th, 2026 5:30 pm
Evolus Q1 Earnings Call Highlights - May 4th, 2026 4:17 pm
Evolus (EOLS) Q2 2025 Earnings Call Transcript - May 4th, 2026 2:34 pm
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook - May 4th, 2026 2:05 pm
How The Evolus (EOLS) Story Is Shifting As Analysts Reset Growth And Valuation Assumptions - Apr 25th, 2026 8:09 pm
April 2026's Leading Growth Stocks With Insider Confidence - Apr 16th, 2026 11:36 am
Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference - Apr 15th, 2026 10:02 pm
Evolus to Report First Quarter Financial Results on May 4, 2026 - Apr 14th, 2026 6:30 am
How The Evolus (EOLS) Investment Story Is Shifting After Softer Guidance And Target Cuts - Apr 11th, 2026 7:08 am
Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization - Apr 7th, 2026 1:35 pm
Telix Appoints David Gill as Non-Executive Director - Apr 1st, 2026 5:53 pm
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference - Mar 31st, 2026 6:00 am
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 20th, 2026 2:05 pm
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference - Mar 15th, 2026 5:32 pm
How The Narrative On Evolus (EOLS) Is Resetting After Cautious 2025 And 2026 Guidance - Mar 12th, 2026 5:13 pm
Why Evolus Stock Soared Today - Mar 4th, 2026 9:05 pm